Sanofi Looks To Climb Consumer Ladder In Boehringer Business Swap
This article was originally published in The Tan Sheet
Executive Summary
A pending agreement includes a $5.2bn cash payment from Boehringer to Sanofi but excludes Boehringer’s consumer product business in China. The brands Sanofi will add to its consumer health lineup include two marketed in the US, Dulcolax constipation relief and Zantac heartburn remedy.
You may also be interested in...
Hypera Buys Boehringer’s Buscopan in Brazil
Hypera has agreed to pay BRL1.3bn to acquire the rights in Brazil to Buscopan and Buscofem from Boehringer Ingelheim.
Sanofi Board Forces Out CEO Chris Viehbacher Amid Lantus Woes
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
Sanofi’s Nasacort First-In-Class Switch Receives FDA Approval
The firm’s Chattem division will bring the 24-hour nasal allergy spray to market in the spring of 2014.